Deramiocel Cell Therapy Shows Promise in Slowing Muscle and Heart Damage in DMD
A phase 3 clinical trial has shown that deramiocel, a cell therapy, can slow muscle weakening and heart damage in boys and young men with advanced Duchenne muscular dystrophy (DMD). The trial, published in The Lancet, involved 106 participants across the U.S. and demonstrated that those receiving deramiocel experienced slower decline in arm movement and better heart function compared to those on a placebo. The therapy, derived from donor heart cells, targets muscle swelling and scarring rather than the genetic mutation itself. While generally safe, some participants experienced mild allergic reactions. 
